GlobeImmune

GlobeImmune is a Louisville, Colorado-based biotechnology company that develops therapeutic vaccines to treat cancer and infectious diseases using its proprietary genetically modified yeast platform. The clinical-stage firm focuses on activating T cells against diseased cells, advancing candidates like GI-6207 and GI-4000 without having any marketed products. Operating as a publicly traded entity, the company secured a $17.5 million Series E round in 2010 and established strategic partnerships with recognizable entities including Celgene, Gilead, and Biogen Idec. These collaborations provided significant capital, such as a $40 million upfront payment from Celgene, though subsequent clinical trial failures led to workforce reductions from its peak of 22 employees. Following the termination of its hepatitis B vaccine partnership, the organization entered an agreement to sell shares to NantCell in 2017. GlobeImmune was founded in 1995 by Donald Bellgrau and Richard Duke.